Triptolide enhances carboplatin-induced apoptosis by inhibiting nucleotide excision repair (NER) activity in melanoma
Authors:
Open Access
- 1 June 2023
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 14, 1157433
Abstract
Introduction:Carboplatin (CBP) is a DNA damaging drug used to treat various cancers, including advanced melanoma. Yet we still face low response rates and short survival due to resistance. Triptolide (TPL) is considered to have multifunctional antitumor effects and has been confirmed to enhance the cytotoxic effects of chemotherapeutic drugs. Herein, we aimed to investigate the knowledge about the effects and mechanisms for the combined application of TPL and CBP against melanoma.Methods:Melanoma cell lines and xenograft mouse model were used to uncover the antitumor effects and the underlying molecular mechanisms of the alone or combined treatment of TPL and CBP in melanoma. Cell viability, migration, invasion, apoptosis, and DNA damage were detected by conventional methods. The rate-limiting proteins of the NER pathway were quantitated using PCR and Western blot. Fluorescent reporter plasmids were used to test the NER repair capacity.Results:Our results showed that the presence of TPL in CBP treatment could selectively inhibit NER pathway activity, and TPL exerts a synergistic effect with CBP to inhibit viability, migration, invasion, and induce apoptosis of A375 and B16 cells. Moreover, combined treatment with TPL and CBP significantly inhibited tumor progression in nude mice by suppressing cell proliferation and inducing apoptosis.Discussion:This study reveals the NER inhibitor TPL which has great potential in treating melanoma, either alone or in combination with CBP.Keywords
This publication has 51 references indexed in Scilit:
- Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer researchCancer Letters, 2012
- DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapyNucleic Acids Research, 2012
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- XPB, a subunit of TFIIH, is a target of the natural product triptolideNature Chemical Biology, 2011
- Mechanisms of Chemoresistance to Alkylating Agents in Malignant GliomaClinical Cancer Research, 2008
- How do real tumors become resistant to cisplatin?Cell Cycle, 2008
- Platinum Resistance: The Role of DNA Repair PathwaysClinical Cancer Research, 2008
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Potential roles for p53 in nucleotide excision repairCarcinogenesis, 1999